Browsing Tag
Inc.
323 posts
Could three FDA submissions turn bezuclastinib into a rare disease and oncology launch engine?
Cogent’s AdvSM NDA gives COGT a third bezuclastinib FDA submission, sharpening its KIT-driven disease franchise and late-2026 launch story.
MacroGenics exits GMP manufacturing operations as Bora expands U.S. biologics footprint
MacroGenics’ $122.5 million Bora sale boosts MGNX cash flexibility while shifting GMP manufacturing to a CDMO model.
Zoom targets buyer intelligence and AI revenue agents with Common Room acquisition
Zoom’s Common Room acquisition strengthens ZM’s AI revenue platform with buyer intelligence, GTM signals and revenue agents.
Is Nasdaq becoming the biggest winner of the 2026 IPO market comeback?
Nasdaq’s $129.3 billion first-half listings record strengthens NDAQ’s IPO market story as AI, aerospace, biotech and energy issuers return.
Rakuten gains JPY148bn Japan backing for AST SpaceMobile satellite network
Japan will provide up to ¥148 billion for a Rakuten-led satellite communications network that could connect ordinary smartphones beyond terrestrial mobile coverage and during major disasters.
Why Micron’s GM agreement matters for MU stock and software-defined vehicle platforms
Micron’s GM supply agreement strengthens MU’s automotive memory story as software-defined vehicles, ADAS and in-cabin AI drive chip demand.
Could nomlabofusp become the rare disease catalyst that revalues Larimar?
Larimar’s rolling BLA and nomlabofusp data sharpen LRMR’s rare disease biotech story around Friedreich’s ataxia, frataxin and accelerated approval.
BridgeBio raises $1bn in preferred equity to fund rare disease product launches
BridgeBio’s $1 billion preferred equity raise strengthens BBIO’s balance sheet as Attruby grows and three rare disease launches approach.
Could Meteor Aerospace give VisionWave a stronger foothold in next-generation defense architecture?
VisionWave’s Meteor Aerospace deal could expand VWAV into unmanned systems, electronic warfare and C4ISR, but closing and dilution risks remain.
Samsung and SK hynix anchor 800tn won South Korea AI chip expansion
South Korea’s 800 trillion won chip plan puts Samsung and SK hynix at the centre of an AI buildout. Read what could derail the strategy.